DHT and Hair Loss Explained: How Dihydrotestosterone Shrinks Follicles

Pattern hair loss affects millions of men and a substantial number of women. The hormone dihydrotestosterone, or DHT, is the primary driver in most cases. Understanding how DHT forms, why it miniaturizes certain follicles, and who is susceptible helps clarify the rationale behind various medications and why individual responses vary.

Dr. Charles Pereyra, a board-certified emergency physician and member of the International Society of Hair Restoration Surgery (ISHRS), performs Micrograft FUE procedures and evaluates follicular health at Springs Rejuvenation Hair clinics in Miami, Los Angeles, Austin, Atlanta, and New York. This page reviews the published science on DHT and hair loss and what the evidence shows about blocking it.

What DHT Is and How the Body Makes It

Dihydrotestosterone is an androgen—a hormone that binds to androgen receptors throughout the body. The enzyme 5-alpha-reductase converts testosterone to DHT, with type II 5-alpha-reductase concentrated in hair follicles and the prostate. DHT is three to five times more potent than testosterone at activating the androgen receptor.

In the 1970s, Imperato-McGinley and colleagues studied men in the Dominican Republic who had a congenital deficiency of 5-alpha-reductase (Imperato-McGinley, 1974). These individuals had normal testosterone levels but low DHT and did not develop male-pattern baldness or prostate enlargement. That natural experiment provided early evidence that DHT, not testosterone itself, mediates many androgen-dependent processes including the miniaturization of scalp follicles.

The conversion of testosterone to DHT occurs in many tissues, but the rate and clinical consequences differ by location. In the scalp, type II 5-alpha-reductase is active within dermal papilla cells and outer root sheath cells of the follicle. Circulating levels of DHT reflect activity in the skin, liver, and prostate combined. Scalp follicle DHT depends on local enzyme activity, which is why systemic DHT measurements do not perfectly predict hair-loss severity. Genetic variation in the enzyme's expression across different follicles contributes to the characteristic patterns of retention and loss seen in androgenetic alopecia.

How DHT Miniaturizes Hair Follicles

DHT binds to androgen receptors in the dermal papilla cells at the base of each follicle. Research by Hibberts and colleagues in 1998 demonstrated that dermal papilla cells from balding scalp contain higher levels of androgen receptors than cells from non-balding scalp (Hibberts, 1998). When DHT binds these receptors, the cells release paracrine factors—signaling molecules that shorten the growth phase (anagen) and shrink the follicle.

Inui and Itami reviewed the molecular cascade in 2011, highlighting transforming growth factor beta (TGF-beta) and dickkopf-1 (DKK-1) as key mediators that inhibit follicle growth (Inui & Itami, 2011). TGF-beta suppresses cell proliferation in the follicle matrix, while DKK-1 inhibits the Wnt signaling pathway required for anagen initiation. Over successive cycles, affected follicles produce finer, shorter hairs until they become vellus—soft, unpigmented strands often described as peach fuzz.

The miniaturization process is gradual. Each hair cycle sees a slight reduction in follicle diameter and anagen duration. Early on, the change may be subtle: hair appears thinner or grows more slowly. Over years, the progressive shrinkage becomes visible as areas of scalp show increased transparency. The follicles do not disappear entirely in most cases; they remain present but produce hair too fine to provide cosmetic coverage.

Randall's 2008 review examined an intriguing paradox: DHT stimulates beard and body-hair growth while shrinking scalp follicles (Randall, 2008). The difference lies in which androgen-responsive genes are activated in each location. Scalp follicles in pattern-loss zones are genetically programmed to respond to DHT with miniaturization, whereas beard follicles respond with terminal-hair growth. This site-specific programming is intrinsic to the follicle and persists even when the follicle is moved to a different location, a principle exploited in hair-restoration procedures.

Why DHT Spares the Back and Sides

The occipital and temporal (back and side) regions of the scalp usually retain hair even in advanced pattern loss. This phenomenon, sometimes called donor dominance, reflects intrinsic differences in follicle biology. Dermal papilla cells from these areas have fewer androgen receptors and are less sensitive to DHT. Why does DHT only affect the top of the head? The answer lies in regional genetic programs established during embryonic development that determine follicle sensitivity to androgens.

When surgeons transplant occipital follicles to the balding crown or hairline, those grafts continue to grow because they carry their original, DHT-resistant characteristics. This behavior underpins follicular-unit extraction and similar procedures. Even when exposed to the same circulating DHT levels and placed in a scalp environment where neighboring follicles are miniaturizing, transplanted occipital follicles maintain their growth.

The exact genetic program that makes occipital follicles resistant is still being mapped. Multiple genes likely contribute, including not only androgen-receptor expression but also local growth-factor production, blood-supply density, and innervation patterns. What is clear from clinical observation is that the resistance is stable and reproducible, making the occipital and lower temporal scalp reliable donor sites for grafts.

Genetics: Androgen Receptor Sensitivity and Inheritance

Is male baldness hereditary? Yes, though the inheritance pattern is complex. A large-scale meta-analysis by Heilmann-Heimbach and colleagues in 2017 identified more than 60 genetic loci associated with male-pattern hair loss (Heilmann-Heimbach, 2017). The androgen receptor gene (AR) sits on the X chromosome, which men inherit from their mothers, but many other risk variants lie on autosomes contributed by both parents. The common notion that hair loss is inherited solely from the maternal grandfather is an oversimplification; both sides of the family contribute genetic risk.

Individual sensitivity to DHT is largely determined by the number and activity of androgen receptors in follicle cells, as well as local 5-alpha-reductase levels. A man may have normal circulating DHT yet experience significant miniaturization if his follicles express high receptor levels or if the receptors in his follicles are particularly sensitive variants. Conversely, another man with similar DHT may retain hair if his follicles are less sensitive. This genetic variation explains why not everyone with male levels of DHT develops pattern loss, and why onset and severity differ widely.

The age of onset also varies. Some men notice thinning in their late teens or early twenties, while others retain most of their hair into middle age or beyond. Early onset often correlates with a family history of significant hair loss and may progress more rapidly. Genetic testing for hair-loss risk is available commercially, but it does not yet guide therapy choice in a clinically validated way. Family history and examination of miniaturization patterns remain the primary assessment tools.

Women also carry androgen receptors and produce DHT, though at lower absolute levels than men. Genetic susceptibility operates in women as well. Female relatives of men with early, severe pattern loss may themselves experience thinning, though the distribution and degree often differ. The genetics of female pattern hair loss overlap with male-pattern loss but are influenced by additional hormonal factors, discussed further below.

DHT Blockers: Prescription, Topical and 'Natural' Options Compared

Several approaches aim to lower DHT or block its effects. What is a DHT blocker? In practice, the term refers to medications that inhibit 5-alpha-reductase (reducing DHT production) or, less commonly, agents that attempt to block the androgen receptor itself. The table below summarizes what the published evidence shows:

Gupta and colleagues performed a network meta-analysis in 2022 comparing the relative efficacy of minoxidil and 5-alpha-reductase inhibitors in androgenetic alopecia (Gupta, 2022). Finasteride and dutasteride were associated with greater increases in hair count than minoxidil alone, though combination use is common and individual responses vary. The analysis drew on data from randomized controlled trials with standardized hair-count endpoints. Real-world results depend on adherence, baseline severity, and individual pharmacogenetics.

Does finasteride increase testosterone? In a sense, yes, though the effect is modest. Finasteride and dutasteride inhibit the conversion of testosterone to DHT, so less testosterone is diverted down that pathway. Serum testosterone may rise by 10 to 15 percent, while DHT falls substantially. Total androgen activity in the body changes little, and most men do not notice systemic effects. The MedlinePlus Medical Encyclopedia notes that finasteride is generally well-tolerated (MedlinePlus, NIH), though a small percentage of users report changes in libido or mood. Those effects are typically reversible when the medication is stopped.

Does blocking DHT lower testosterone? No; as explained above, blocking the conversion raises testosterone modestly rather than lowering it. The primary goal of these medications is to reduce follicle exposure to DHT without significantly altering other androgen-dependent functions. Clinical trials have monitored hormone levels and found that the changes do not produce unwanted virilization or feminization in men.

Natural DHT blockers like saw palmetto extract and pumpkin seed oil are marketed widely, but the clinical evidence is limited to a few small trials with mixed results. Saw palmetto is derived from the fruit of Serenoa repens and has been studied primarily for benign prostatic hyperplasia, with some investigators proposing a mild 5-alpha-reductase inhibitory effect. A handful of small hair-loss trials have shown modest improvements in hair density, but these studies often lacked rigorous controls, had short follow-up periods, and did not measure DHT levels directly. The potency of these natural products in reducing DHT is not comparable to finasteride. Supplements are not held to the same regulatory standards as prescription medications, so dosing and purity vary between brands. Individuals considering any supplement should discuss it with a physician to weigh potential benefits against realistic expectations.

DHT in Women and Other Causes of Thinning

DHT and hair loss can occur in women, though the pattern and causes are often more complex than in men. Women produce androgens—including testosterone and DHT—at lower absolute levels than men, but follicle sensitivity can still lead to miniaturization. Female-pattern hair loss typically presents as diffuse thinning over the crown rather than a receding hairline or vertex balding. The StatPearls review on androgenetic alopecia notes that women may experience hair thinning at any age, and the role of androgens is less straightforward than in men (Ho, Sood & Zito, 2024).

Other factors frequently contribute in women, including iron deficiency, thyroid disorders (both hypothyroidism and hyperthyroidism), hormonal fluctuations related to pregnancy or menopause, polycystic ovary syndrome, and autoimmune conditions such as alopecia areata. Some women with elevated androgens (for example, due to polycystic ovary syndrome) may have higher DHT levels and more pronounced pattern thinning, but many women with normal androgen levels also experience hair loss. The interplay of estrogen, progesterone, and androgens, along with non-hormonal factors, makes female hair loss more heterogeneous.

Finasteride is not FDA approved for use in women, and its safety in women of childbearing potential is not established due to the risk of birth defects if a male fetus is exposed. Dutasteride carries similar concerns. Minoxidil is FDA approved for women and is often a first-line option. Spironolactone, an anti-androgen medication, is sometimes used off-label in women with evidence of hyperandrogenism, though the evidence for its efficacy in female-pattern hair loss is limited.

Because the causes of hair thinning in women are multifactorial, a thorough evaluation—including history, examination, and sometimes laboratory work to assess thyroid function, iron stores, and androgen levels—is important before attributing loss solely to DHT. Scalp biopsy is occasionally performed when the diagnosis is uncertain. A comprehensive assessment helps direct therapy to the most likely underlying factors.

Assessing an individual's hair loss involves reviewing family history, examining follicle miniaturization patterns using magnification, and discussing goals and expectations. Dr. Pereyra offers a Follicular Health Assessment at Springs Rejuvenation Hair locations in Miami (Aventura), Los Angeles, Austin, Atlanta, and New York. For more information or to schedule a consultation, call (888) 503-4482.

Medical disclaimer: Stem cell and exosome therapy is not an FDA approved therapy and is considered to be in the experimental stages; it is not FDA approved to treat any disease. These statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. This page is educational and is not medical advice; always consult a qualified physician. Written and reviewed for medical accuracy by Dr. Charles Pereyra, MD, Medical Director, Springs Rejuvenation Hair.